KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Change in Cash: 2018-2025

Historic Change in Cash for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to $3.3 million.

  • Castle Biosciences' Change in Cash fell 64.60% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$9.4 million, marking a year-over-year decrease of 351.69%. This contributed to the annual value of $20.9 million for FY2024, which is 186.56% up from last year.
  • Castle Biosciences' Change in Cash amounted to $3.3 million in Q3 2025, which was up 144.57% from -$7.5 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Change in Cash ranged from a high of $24.8 million in Q4 2024 and a low of -$139.0 million during Q3 2022.
  • Moreover, its 3-year median value for Change in Cash was -$4.7 million (2023), whereas its average is -$3.4 million.
  • Per our database at Business Quant, Castle Biosciences' Change in Cash slumped by 2,592.48% in 2022 and then soared by 301.83% in 2024.
  • Quarterly analysis of 5 years shows Castle Biosciences' Change in Cash stood at -$33.5 million in 2021, then spiked by 66.52% to -$11.2 million in 2022, then surged by 167.82% to $7.6 million in 2023, then soared by 224.89% to $24.8 million in 2024, then plummeted by 64.60% to $3.3 million in 2025.
  • Its Change in Cash was $3.3 million in Q3 2025, compared to -$7.5 million in Q2 2025 and -$30.0 million in Q1 2025.